Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki (“Wojcicki”) of 23andMe breached their fiduciary duties in connection with Wojcicki’s ongoing effort to purchase all 23andMe shares she does not already own.
If you are a holder of 23andMe, you are encouraged to submit your information at: https://www.bfalaw.com/cases-investigations/23andme-holding-co.
Investigation Details:
On July 29, 2024, CEO Wojcicki submitted a non-binding proposal to 23andMe to acquire all shares of 23andMe that were not already owned by Wojcicki or her affiliates.
By letter dated August 2, 2024, a Special Committee of the Board of Directors of 23andMe rejected that offer, noting that it “provide[d] no premium to the closing price per share on Wednesday, July 31st, it lack[ed] committed financing, and it [was] conditional in nature.”
In a letter dated September 17, 2024, all the independent directors of 23andMe resigned “effective immediately.” When resigning, the independent directors stated that “[a]fter months of work, we have yet to receive from you a fully financed, fully diligenced, actionable proposal that is in the best interests of the non-affiliated shareholders. We believe the Special Committee and the Board have provided ample time for you to submit such a proposal. That we have not seen any notable progress over the last 5 months leads us to believe no such proposal is forthcoming. . . . [I]t is also clear that we differ on the strategic direction for the Company going forward. Because of that difference and because of your [Wojcicki’s] concentrated voting power, we believe that it is in the best interests of the Company’s shareholders that we resign from the Board rather than have a protracted and distracting difference of view with you as to the direction of the Company.”
BFA is concerned that the board of directors of 23andMe and Wojcicki may have breached their fiduciary duties as part of these events for, among other reasons, failing to prioritize the value of the company, and engaging in potentially self-interested dealing. BFA intends to take all actions necessary to protect the interests of 23andMe stockholders and to ensure that the fiduciaries are held accountable for any and all breaches of their fiduciary duties.
Click here if you are a holder of 23andMe: https://www.bfalaw.com/cases-investigations/23andme-holding-co
What Can You Do?
If you are a current holder of 23andMe Holding Co. stock, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/23andme-holding-co
Or contact:Ross Shikowitzross@bfalaw.com212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/23andme-holding-co
Attorney advertising. Past results do not guarantee future outcomes.
Health care stocks were steady premarket Wednesday with the iShares Biotechnology ETF unchanged and the Health Care Select Sector SPDR Fund up by a slight 0.1% recently.
Organon said it has agreed to acquire Roivant's Dermavant, including its flagship dermatological cream Vtama, for a total consideration of $1.2 billion. Roivant Sciences shares were up nearly 4% pre-bell.
TG Therapeutics shares advanced by over 6% after the company said updated data from a phase 3b trial showed that rapid 30-minute infusions of BRIUMVI (ublituximab) are well tolerated in patients suffering from relapsing forms of multiple sclerosis.
23andMe Holding's independent directors resigned after receiving an unsatisfactory take-private offer from Chief Executive Anne Wojcicki, Reuters reported, citing an internal document. 23andMe Holding shares fell past 9% pre-bell.
On Tuesday, the independent directors of the Board of 23andMe Holding Co. sent a letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, providing their resignation, effective immediately.
The board said, “After months of work, we have yet to receive from you a fully financed, fully diligenced, actionable proposal that is in the best interests of the non-affiliated shareholders. We believe the Special Committee and the Board have provided ample time for you to submit such a proposal. That we have not seen any notable progress over the last 5 months leads us to believe no such proposal is forthcoming. The Special Committee is therefore unwilling to consider further extensions...”
In April, Anne Wojcicki started contemplating taking the genetics testing company private.
Founded in 2006, 23andMe went public in 2021 via a merger with a special purpose acquisition company, a deal that valued 23andMe at around $3.5 billion. The company witnessed a significant decline in its valuation, once at $6 billion.
Wojcicki, the former spouse of Google founder Sergey Brin, emphasized her opposition to any other buyer acquiring the company.
Wojcicki had initially said it plans to take the company private at 40 cents per share. In August, the Special Committee rejected and, in a letter, said, “We are disappointed with the proposal for multiple reasons, including because it provides no premium, it lacks committed financing, and it is conditional in nature.”
“Therefore, we are not prepared to move forward under the terms provided. Importantly, we request that you immediately withdraw your stated intent to oppose any alternative transaction so that we can fully assess whether there is interest from third parties in a transaction that would maximize value for all shareholders.”
Bloomberg report highlighted that Anne Wojcicki reaffirmed her commitment to privatizing the company.
In a memo obtained by Bloomberg News, Wojcicki expressed her belief that operating outside the constraints of public markets would better align with the company’s long-term mission and goals, stating, “I remain convinced that taking 23andMe private presents the best path to achieving sustainable success.”
She said she would start identifying new board members immediately.
Price Action: ME stock closed at $0.34 on Tuesday.
Read Next:
Photo via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
** Shares of genetic testing firm 23andMe ME.O down 6.80% at 31 cents premarket
** Independent directors said late on Tuesday they have resigned from co's board after not receiving a satisfactory take-private offer from CEO Anne Wojcicki
** "After months of work, we have yet to receive from you a fully financed, fully diligenced, actionable proposal that is in the best interests of the non-affiliated shareholders" - directors said in a letter
** Earlier this month, Wojcicki said would be open to considering third-party takeover proposals for co
** CEO has been trying to take the company private since April
** Up to last close, stock down ~62% YTD
(Reporting by Sriparna Roy in Bengaluru)
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.